Portnoy, Jay
Ciaccio, Christina E.
Beausoleil, Janet
Du Toit, George
Fineman, Stanley
Tilles, Stephen A.
Zhang, June
Lawrence, Claire
Yassine, Mohamed
Mustafa, S Shahzad
Funding for this research was provided by:
Aimmune Therapeutics
Article History
Received: 10 December 2021
Accepted: 13 March 2022
First Online: 9 May 2022
Declarations
:
: Not applicable.
: Not applicable.
: Dr. Portnoy served on an advisory board for Aimmune Therapeutics. Dr. Ciaccio has served on advisory boards for Aimmune Therapeutics. Dr. Beausoleil served on an advisory board for Aimmune Therapeutics. Dr. du Toit served on an advisory board for Aimmune Therapeutics, is an Aimmune Therapeutics Scientific Board Member, an Aimmune Symposium Speaker, and a clinical Investigator on ARC 008, 004, and 005 Trials. Dr. Fineman served on an advisory board for Aimmune Therapeutics, has conducted clinical research with Aimmune Therapeutics, Alladapt, and DBV, and speakers bureau for Taketa, and Biocryst. Dr. Mustafa served on an advisory board for Aimmune Therapeutics and speakers bureau for Genentech, Regeneron, GSK, AstraZeneca, CSL Behring. Dr. Zhang served on an advisory board for Aimmune Therapeutics. Dr. Tilles and Dr. Yassine are employees of Aimmune Therapeutics, a Nestlé Health Science company. Acaster Lloyd Consulting was paid a fixed fee by Aimmune Therapeutics for their role in the design and execution of the study.